Evidence map›Paper›PMID 29156734›Full record

ArticleOncotarget2017

PAX3d mRNA over 2.76 copies/µL in the bloodstream predicts cutaneous malignant melanoma relapse.

Chiara Autilio, Carmela Paolillo, Maria Michela Lavieri, Krizia Pocino, Elisa De Paolis, Enrico Di Stasio, Paolo Marchetti, Cappellini Antonini Gian Carlo, Ettore Capoluongo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chiara AutilioInstitute of Clinical Biochemistry, Laboratory of Clinical Molecular Diagnostics, Fondazione Policlinico "A. Gemelli", Catholic University of the Sacred Heart, Rome, Italy.
Carmela PaolilloInstitute of Clinical Biochemistry, Laboratory of Clinical Molecular Diagnostics, Fondazione Policlinico "A. Gemelli", Catholic University of the Sacred Heart, Rome, Italy.
Maria Michela LavieriUnit of Dermatology, "Cristo Re" Hospital, Rome, Italy.
Krizia PocinoInstitute of Clinical Biochemistry, Laboratory of Clinical Molecular Diagnostics, Fondazione Policlinico "A. Gemelli", Catholic University of the Sacred Heart, Rome, Italy.
Elisa De PaolisInstitute of Clinical Biochemistry, Laboratory of Clinical Molecular Diagnostics, Fondazione Policlinico "A. Gemelli", Catholic University of the Sacred Heart, Rome, Italy.
Enrico Di StasioLaboratory of Clinical Biochemistry, Fondazione Policlinico "A. Gemelli", Rome, Italy.
Paolo MarchettiSant'Andrea Hospital, Rome, Italy.
Cappellini Antonini Gian CarloOncology Unit Immacolata Dermatological Institute (IDI), Rome, Italy.
Ettore CapoluongoInstitute of Clinical Biochemistry, Laboratory of Clinical Molecular Diagnostics, Fondazione Policlinico "A. Gemelli", Catholic University of the Sacred Heart, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to evaluate if our molecular algorithm, based on tumor circulating transcripts, may predict relapse risk in cutaneous malignant melanoma (CMM).

resultsThe multi-marker panel was able to differentiate patients with CMM from HC with high diagnostic sensitivity and specificity, especially for MITF-m and TGFB2 (91-100%) whose levels decreased during follow-up of recurrence-free patients, and remained stable in the case of relapse. PAX3d higher than 2.76 copies/µL emerged as a promising biomarker [specificity = 75-93% and negative predictive value = 75-98%] to stratify subjects at high risk of CMM recurrence independently of age, gender and AJCC staging [OD = 9.5(3.2-28.0), MATERIALS AND

methodsPeripheral blood was collected from 111 CMM patients and from 87 healthy controls (HC) randomly selected. Each specimen was examined by qRT-PCR analysis for the expression of 3 tumor-related transcripts (PAX3d, MITF-m and TGFB2) at diagnosis, and at the following 6 and 12 months during clinical monitoring.

conclusionsWe demonstrated the usefulness of our molecular algorithm to indirectly detect circulating melanoma cells in blood, along with PAX3d capability to assess patients' progression and relapse prediction.

Indexed as

circulating tumor cellsmelanoma molecular biomarkermelanoma relapsePAX3qRT-PCR

Identifiers

PMID29156734
PMCPMC5689624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.